Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method

BIOLOGICAL3 trials

Sponsors

Baxalta now part of Shire

Conditions

Hemophilia A

Phase 1

BAX 855 Dose-Escalation Safety Study

CompletedNCT01599819

Baxalta now part of ShireHemophilia A

Start: 2011-09-30End: 2012-07-27Updated: 2021-05-05

Phase 2

Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)

CompletedNCT01736475

Baxalta now part of ShireHemophilia A

Start: 2013-01-31End: 2014-07-17Updated: 2021-05-20

Phase 3

BAX 855 Pediatric Study

CompletedNCT02210091

Baxalta now part of ShireHemophilia A

Start: 2014-10-31End: 2015-10-23Updated: 2021-05-24

Related Papers

Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: A critical review from the physician's perspective.

2022-04-0413 citations

Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients.

2019-09-254 citations

Immunogenicity of BAX 855 in Previously Treated Patients with Congenital Severe Hemophilia Α

Blood2016-12-022 citations

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A

Blood2015-07-08250 citations